These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 34048112)

  • 1. Facile Approach to C-Glucosides by Using a Protecting-Group-Free Hiyama Cross-Coupling Reaction: High-Yielding Dapagliflozin Synthesis.
    Vaňková K; Rahm M; Choutka J; Pohl R; Parkan K
    Chemistry; 2021 Jul; 27(41):10583-10588. PubMed ID: 34048112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Facile Approach to C-Glucosides by Using a Protecting-Group-Free Hiyama Cross-Coupling Reaction: High-Yielding Dapagliflozin Synthesis.
    Vaňková K; Rahm M; Choutka J; Pohl R; Parkan K
    Chemistry; 2021 Jul; 27(41):10488. PubMed ID: 34180093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dapagliflozin, an oral sodium glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus.
    Calado J
    IDrugs; 2009 Dec; 12(12):785-98. PubMed ID: 19943222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dapagliflozin: A Sodium Glucose Cotransporter 2 Inhibitor for the Treatment of Diabetes Mellitus.
    Davis PN; Ndefo UA; Oliver A
    J Pharm Pract; 2016 Apr; 29(2):165-71. PubMed ID: 25609661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereoselective C-glycosylation reactions with arylzinc reagents.
    Lemaire S; Houpis IN; Xiao T; Li J; Digard E; Gozlan C; Liu R; Gavryushin A; Diène C; Wang Y; Farina V; Knochel P
    Org Lett; 2012 Mar; 14(6):1480-3. PubMed ID: 22385274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of the sodium-glucose co-transporter 2 inhibitor dapagliflozin for the treatment of patients with type 2 diabetes mellitus.
    Gerich JE; Bastien A
    Expert Rev Clin Pharmacol; 2011 Nov; 4(6):669-83. PubMed ID: 22111852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus.
    Shah NK; Deeb WE; Choksi R; Epstein BJ
    Pharmacotherapy; 2012 Jan; 32(1):80-94. PubMed ID: 22392830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereoselective Preparation of α- C-Vinyl/Aryl Glycosides via Nickel-Catalyzed Reductive Coupling of Glycosyl Halides with Vinyl and Aryl Halides.
    Liu J; Gong H
    Org Lett; 2018 Dec; 20(24):7991-7995. PubMed ID: 30525666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of dapagliflozin in children and adolescents with type 2 diabetes mellitus.
    Tirucherai GS; LaCreta F; Ismat FA; Tang W; Boulton DW
    Diabetes Obes Metab; 2016 Jul; 18(7):678-84. PubMed ID: 27291448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
    Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
    Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
    Meng W; Ellsworth BA; Nirschl AA; McCann PJ; Patel M; Girotra RN; Wu G; Sher PM; Morrison EP; Biller SA; Zahler R; Deshpande PP; Pullockaran A; Hagan DL; Morgan N; Taylor JR; Obermeier MT; Humphreys WG; Khanna A; Discenza L; Robertson JG; Wang A; Han S; Wetterau JR; Janovitz EB; Flint OP; Whaley JM; Washburn WN
    J Med Chem; 2008 Mar; 51(5):1145-9. PubMed ID: 18260618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Saxagliptin/Dapagliflozin: A Review in Type 2 Diabetes Mellitus.
    Garnock-Jones KP
    Drugs; 2017 Mar; 77(3):319-330. PubMed ID: 28176222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease.
    Reifsnider OS; Kansal AR; Gandhi PK; Cragin L; Brand SB; Pfarr E; Fahrbach K; Ustyugova A
    BMJ Open Diabetes Res Care; 2021 May; 9(1):. PubMed ID: 33941549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study.
    Seong JM; Kim JJ; Kim HJ; Sohn HS
    Cardiovasc Diabetol; 2020 Jun; 19(1):95. PubMed ID: 32571319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.
    Shimizu M; Suzuki K; Kato K; Jojima T; Iijima T; Murohisa T; Iijima M; Takekawa H; Usui I; Hiraishi H; Aso Y
    Diabetes Obes Metab; 2019 Feb; 21(2):285-292. PubMed ID: 30178600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus.
    Shao H; Zhai S; Zou D; Mir MU; Zawadzki NK; Shi Q; Liu S; Shi L
    Curr Med Res Opin; 2017 Feb; 33(2):359-369. PubMed ID: 27817216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dapagliflozin: an emerging treatment option in type 2 diabetes.
    Kipnes M
    Expert Opin Investig Drugs; 2009 Mar; 18(3):327-34. PubMed ID: 19243283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
    Pollock C; Stefánsson B; Reyner D; Rossing P; Sjöström CD; Wheeler DC; Langkilde AM; Heerspink HJL
    Lancet Diabetes Endocrinol; 2019 Jun; 7(6):429-441. PubMed ID: 30992195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dapagliflozin promotes beta cell regeneration by inducing pancreatic endocrine cell phenotype conversion in type 2 diabetic mice.
    Wei R; Cui X; Feng J; Gu L; Lang S; Wei T; Yang J; Liu J; Le Y; Wang H; Yang K; Hong T
    Metabolism; 2020 Oct; 111():154324. PubMed ID: 32712220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dapagliflozin Inhibits Cell Adhesion to Collagen I and IV and Increases Ectodomain Proteolytic Cleavage of DDR1 by Increasing ADAM10 Activity.
    Okada J; Yamada E; Saito T; Yokoo H; Osaki A; Shimoda Y; Ozawa A; Nakajima Y; Pessin JE; Okada S; Yamada M
    Molecules; 2020 Jan; 25(3):. PubMed ID: 31979355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.